McDermott Laboratories Limited (t.a. Gerard Laboratories), Medis International a.s., Mylan Germany GmbH, Mylan Hungary Kft.
PolandAll drugs from this manufacturer
-
The medicine is used in adults to reduce the risk of another heart attack or to reduce the risk of death from cardiovascular disease (e.g., after acute coronary syndrome). It is also used to reduce the risk of blood clots in people with coronary artery disease or peripheral artery disease.
Dosage form: tablets, film-coated
Active substance Dosage rivaroxaban 2.5 mg ATC: B01AF01
-
The medicine is used in adults to prevent the formation of blood clots in the veins after hip or knee replacement surgery, and to treat deep vein thrombosis and pulmonary embolism, as well as to prevent their recurrence.
Dosage form: tablets, film-coated
Active substance Dosage rivaroxaban 10 mg ATC: B01AF01
-
VIXARGIO is used in adults to prevent strokes and blood clots (in atrial fibrillation) and to treat and prevent blood clots in the leg veins and pulmonary vessels. In children and adolescents (weighing more than 30 kg), it is used to treat blood clots after initial injectable treatment.
Dosage form: tablets, film-coated
Active substance Dosage rivaroxaban 15 mg ATC: B01AF01
-
VIXARGIO is used in adults to prevent strokes and other blood clots (e.g., in atrial fibrillation) and to treat deep vein thrombosis and pulmonary embolism. In children and adolescents (weighing more than 30 kg), it is used to treat and prevent recurrent blood clots in the veins or lungs.
Dosage form: tablets, film-coated
Active substance Dosage rivaroxaban 20 mg ATC: B01AF01
-
The medicine is used in adults to treat deep vein thrombosis (in the legs) and pulmonary embolism, as well as to prevent the recurrence of blood clots in the blood vessels of the legs and lungs.
Dosage form: tablets, film-coated
Active substance Dosage rivaroxaban 15 mg or 20 mg ATC: B01AF01